Leal therapeutics is developing novel therapeutics for central nervous system disorders. The company has yet to reveal much information about their therapeutics and scientific approach. The company’s CEO, Asa Abeliovich, has noted that Leal will work on oligonucleotide-based therapeutics and have a broad focus that includes psychiatric and neurodegenerative diseases. One of the key challenges and thus innovations for Leal will be oligonucleotide delivery within the brain. Leal will target patients who, based on genetic and other data, are likely to respond positively to specific drugs. During treatment, Leal plans to monitor biomarker data to determine the effectiveness of their therapeutics.
Claim company profile to post jobs directly on this page and this website.